GH Research PLC (GHRS): Price and Financial Metrics
GHRS Price/Volume Stats
| Current price | $11.19 | 52-week high | $14.64 |
| Prev. close | $10.99 | 52-week low | $5.05 |
| Day low | $10.78 | Volume | 250,600 |
| Day high | $11.31 | Avg. volume | 137,400 |
| 50-day MA | $9.61 | Dividend yield | N/A |
| 200-day MA | $9.00 | Market Cap | 582.19M |
GHRS Stock Price Chart Interactive Chart >
GH Research PLC (GHRS) Company Bio
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that is being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate that is in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was founded in 2018 and is based in Dublin, Ireland.
Latest GHRS News From Around the Web
Below are the latest news stories about GH RESEARCH PLC that investors may wish to consider to help them evaluate GHRS as an investment opportunity.
We're Hopeful That GH Research (NASDAQ:GHRS) Will Use Its Cash WiselyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
11 Most Promising Psychedelic Stocks According to Hedge FundsIn this piece, we will take a look at the 11 most promising psychedelic stocks according to hedge funds. If you want to skip our overview of the psychedelic industry and the latest news, then you can take a look at the 5 Most Promising Psychedelic Stocks. The ability to use chemicals to alter one’s […] |
15 Best Falling Stocks To Buy NowIn this article, we will take a detailed look at the 15 Best Falling Stocks To Buy Now. For a quick overview of such stocks, read our article 5 Best Falling Stocks To Buy Now. The Wall Street is headed to end 2023 on a strongly positive note as the Fed’s indication of coming rate cuts have infused a […] |
GH Research Drags Down Psychedelic Drug Stocks Index By 7%The 5 constituents in the Psychedelic Drug Stocks Index continue to exhibit extreme volatility week after week. |
GH Research Reports Third Quarter Financial Results and Provides Business UpdatesDUBLIN, Ireland, Nov. 09, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2023, and provided business updates. Third Quarter 2023 Financial Highlights Cash position Cash, cash equivalents, other financial assets and marketable securities were $228.7 million as of September 30, 2023, compar |
GHRS Price Returns
| 1-mo | 1.73% |
| 3-mo | 91.28% |
| 6-mo | 53.71% |
| 1-year | 36.63% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 92.93% |
| 2023 | -40.33% |
| 2022 | -58.34% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...